 |
|
Visual Risks of Facial Fracture Repair in the Setting of Traumatic Optic Neuropathy
Terry Y. Shibuya, MD;
Steven M. Feinberg, MD;
Robert H. Mathog, MD;
Kuo-Tung Li, MS;
S. Alex Kim, MD;
Robert J. Stachler, MD;
George H. Yoo, MD
Arch Otolaryngol Head Neck Surg. 2006;132:258-264.
Objective To identify whether facial fracture repair in patients with traumatic optic neuropathy results in visual deterioration.
Design A retrospective analysis was performed of all patients admitted from 1992 through 1997 with the diagnosis of facial fracture and traumatic optic neuropathy. Vision was recorded before and after fracture repair using logarithm of the minimum angle of resolution measurements. Visual outcome was compared with a nonsurgically treated group of patients with a similar diagnosis.
Setting University trauma hospital.
Patients A total of 700 medical charts were reviewed, and 54 patients met study criteria. All patients received megadose corticosteroid treatment and were divided into 3 groups: (1) facial fracture repair alone, (2) optic nerve decompression (OND) + facial fracture repair, or (3) nonsurgical treatment.
Results For the 16 patients in the fracture repair alone group, 12 (75%) had improved vision and 4 (25%) had no change postoperatively. For the 10 patients in the OND + fracture repair group, 3 (30%) had improved vision, 5 (50%) had no change, and 2 (20%) had worsened vision postoperatively. For the 28 patients in the nonsurgical group, 18 (64%) had improved vision, 9 (32%) had no change, and 1 (4%) had worsened vision by discharge. Facial fracture repair alone and the nonsurgical groups both demonstrated significant visual improvement by discharge. The amount of improvement was not significantly different between all 3 groups (facial fracture repair, 0.38 ± 0.40; OND + facial fracture repair; 0.32 ± 1.38; and nonsurgical, 0.69 ± 1.07).
Conclusions Facial fracture repair in the setting of traumatic optic neuropathy had no adverse effect on vision. Patients requiring OND + fracture repair had a significantly worse visual prognosis.
Author Affiliations: Department of Otolaryngology/Head & Neck Surgery, University of California Irvine School of Medicine (Drs Shibuya and Feinberg), and Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center (Dr Shibuya and Mr Li), Orange; and Department of Otolaryngology/Head & Neck Surgery, Wayne State University School of Medicine, Detroit, Mich (Drs Mathog, Kim, Stachler, and Yoo).
|
